ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年05月25日 10時00分
Source:
Eisai
エーザイ、MSDとの「レンバチニブ」の切除不能な肝細胞がんに係る承認申請の米国FDAによる審査終了目標日延長について
東京, 2018年05月25日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とMerck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)は、このたび、米国におけるキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)の「切除不能な肝細胞がん」に係る適応追加申請について、米国食品医薬品局(Food and Drug Administration: FDA)によるPDUFA(Prescription Drug User Fee Act)アクション・デート(審査終了目標日)が延長されたことをお知らせします。
FDAより、本申請の審査に追加の時間が必要であり、本アクションデートを延長する旨の連絡がありました。FDAによると、審査は従来のPDUFAアクション・デート(2018年5月24日)の3カ月後となる2018年8月24日までに完了する予定です。3カ月はFDAの延長期間として標準的なものです。
エーザイは申請者として、引き続きFDAの審査に協力してまいります。
「レンビマ」は、米国において「局所再発又は転移性、進行性、放射性ヨウ素治療抵抗性分化型甲状腺がん」、および「血管新生阻害薬の前治療歴を有する進行性腎細胞がんに対するエベロリムスとの併用療法」の適応で承認を取得しています。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201839.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Honda Koraidon First Showrun during Suzuka 8 Hours
Jul 18, 2025 11:06 JST
SJC2 optical submarine cable in operation
Jul 18, 2025 09:36 JST
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
Jul 17, 2025 19:07 JST
Mitsubishi Motors Premieres the All-New Destinator in Indonesia
Jul 17, 2025 17:21 JST
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector
Jul 17, 2025 14:16 JST
"TOKIO Exciting Anime Workshop" Confirmed - Enjoy "Summer Festival at Anime Tokyo Station" This Summer Vacation
Jul 17, 2025 11:00 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Jul 16, 2025 14:50 JST
New Trains for Singapore's Sengkang-Punggol LRT Begin Commercial Operation
Jul 16, 2025 14:34 JST
AUG East Consortium and NEC to develop high-capacity submarine cable system across East Asia
Jul 16, 2025 14:00 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition - New Designs Added for Admission Bonus Illustration Cards
Jul 16, 2025 11:00 JST
Fujitsu Data Intelligence PaaS enhances Mazda's data-utilization and decision-making
Jul 16, 2025 10:30 JST
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection
Jul 16, 2025 10:20 JST
All Nippon Airways and Hitachi Unveil Japan's First Airline "Operations Brain" System, Enabling Rapid, Optimal Flight Schedule Revisions During Disruptions
Jul 15, 2025 12:00 JST
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
Jul 09, 2025 19:02 JST
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 08, 2025 20:30 JST
More Latest Release >>
Related Release
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
7/14/2025 10:20:00 AM JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
7/8/2025 9:31:00 AM JST
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
6/2/2025 5:46:00 PM JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
5/28/2025 5:45:00 PM JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
5/21/2025 3:00:00 PM JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
5/16/2025 5:21:00 PM JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
More Press release >>